AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s share price shot up 11% during trading on Friday . The stock traded as high as $2.94 and last traded at $2.93. 1,813,400 shares changed hands during trading, a decline of 41% from the average session volume of 3,094,505 shares. The stock had previously closed at $2.64.

A number of brokerages recently issued reports on AVEO. Zacks Investment Research lowered shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 16th. B. Riley began coverage on shares of AVEO Pharmaceuticals in a research report on Monday, November 13th. They issued a “buy” rating and a $5.00 target price for the company. began coverage on shares of AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 target price for the company. Finally, Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. AVEO Pharmaceuticals currently has an average rating of “Buy” and an average target price of $4.05.

The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of -0.32.

A number of institutional investors and hedge funds have recently made changes to their positions in AVEO. Fore Research & Management LP bought a new position in shares of AVEO Pharmaceuticals during the 2nd quarter valued at about $111,000. Victory Capital Management Inc. bought a new position in shares of AVEO Pharmaceuticals during the 3rd quarter valued at about $164,000. Rehmann Capital Advisory Group bought a new position in shares of AVEO Pharmaceuticals during the 3rd quarter valued at about $193,000. OxFORD Asset Management LLP bought a new position in shares of AVEO Pharmaceuticals during the 3rd quarter valued at about $228,000. Finally, Cannell Peter B & Co. Inc. boosted its position in shares of AVEO Pharmaceuticals by 22.9% during the 2nd quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 20,500 shares in the last quarter. Hedge funds and other institutional investors own 50.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/aveo-pharmaceuticals-aveo-shares-up-11/1755082.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.